The use of liquid silicone for soft tissue augmentation has been in practice for the last 40 years. Initially thought to be inert, provoking little local and no systemic response, liquid silicone was extensively used for cosmetic sub‐cutaneous augmentation. With its rampant and unregulated use, however, this substance has become implicated in a variety of adverse reactions, some of which occur months to years after initial exposure. We report the case of a male‐to‐female transsexual patient who had received liquid silicone hip injections for cosmetic augmentation. Years after receiving these injections she developed silicone‐induced granulomas causing hypercalcemia and subsequent renal failure. We discuss the controversy over the use of liquid silicone for soft tissue augmentation. In addition, the pathophysiology of granulomatous disease causing hypercalcemia and treatment options for sili‐cone‐induced granulomas is discussed.